QIAGEN Launches Major New Product Line for Protein Sample Preparation
Jan 12 2005

QIAGEN Launches Major New Product Line for Protein Sample Preparation

Positions QIAGEN as a Leading Provider for Proteomic Sample Fractionation Kits


Venlo, The Netherlands, Janury 12, 2005 - QIAGEN N.V. (Nasdaq: QGENF; Frankfurt , Prime Standard: QIA) one of the world's leading providers of innovative enabling technologies and products for the separation, purification and handling of nucleic acids today announced the launch of a substantial new product offering branded as the Qproteome product line. QIAGEN believes that this Qproteome product line represents one of the broadest, most comprehensive and technologically most advanced solution portfolios for the fractionation of proteins and will allow rapid conversion of today's applied methods which are mainly based on home-brew protocols.

Fractionation and depletion of proteins are among the most widely used methodologies in preanalytical sample preparation of proteins and allow scientists to create subclasses of proteins required for subsequent analysis. Protein fractionation and depletion protocols are increasingly used in parallel to and in combination with nucleic acid sample preparation and analysis products. The quality of the fractionation is key to the sensitivity and reliability of analysis technologies such as PAGE (protein analysis gel electrophoresis) and mass spectrometry, enabling scientists to identify and validate diagnostic markers or drug targets in academics, biopharmaceutical and biomedical fields.

QIAGEN's Qproteome kits provide reagents buffers and consumable column and bead formats in easy to use kit solutions. The kits leverage novel and proprietary separation technologies and are designed to either reduce the complexity of the proteome or to fractionate complex protein samples for subsequent analysis - thereby enabling our customers to separate, purify and characterize lower-abundance proteins from complex proteomes. The portfolio of easy-to-use kits includes kits that separate proteins either on the basis of glycosylation patterns, their sub-cellular localization, their affinity to nucleic acids, or their overall solubility. These kits can also be used to localize or characterize biomarkers in cells grown under different conditions or isolated from different tissues.

An additional kit is available for depletion of albumin and IgG from serum or plasma samples. The depletion facilitates analysis of low-abundance blood proteins, which otherwise may be obscured by the presence of large proportion of albumin and IgG in the sample. Separation is fast, efficient, and reproducible and delivers active protein into distinct fractions, ready for further downstream analysis.

QIAGEN also announced the launch of the first kits in the Qproteome product line that co-purify nucleic acids and protein content in one procedure and expects to launch a significant number of further products.

QIAGEN brings to this effort its unique expertise in sample preparation, its market- and technology leading position in the purification of phosphoproteins and recombinant 6xHis tagged proteins and extensive collaborations with several partners in the analytical and proteomic fields including GALAB Technologies GmbH, ProteoSys AG and the Australian Proteome Analysis Facility (APAF).

"Modern system biology analyzes gene-protein and protein-protein relationships and interactions," said Dr. Joachim Schorr, QIAGEN's Senior Vice President of R&D. "With the launch of the Qproteome product line QIAGEN is now providing substantially more efficient tools to the rapidly growing customer base which leverages systems biology in both research and molecular diagnostics. The broad portfolio of novel and proprietary technologies incorporated in this new product offering creates a new dimension in performance."

"We are pleased to announce the launch of this new product line which is based on both novel QIAGEN technologies and innovative technologies we acquired or licensed from numerous external partners," said Dr. Achim Ribbe, QIAGEN's Executive Director Corporate Business Development. "We are also pleased to announce that QIAGEN is now positioned to extend its leading position in recombinant protein sample preparation into the non-recombinant protein sample preparation market."



QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany , the United States , Japan , the United Kingdom , Switzerland , France , Italy , Australia , Norway , Austria , Canada , and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.


Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).






Phone: +49 2103 29 11710

Fax: +49 2103 29 21710

Email ir@qiagen.com


Share this page